Cogstate Ltd. (ASX: CGS) (OTCQX: COGZF): Democratizing Brain Health Assessments [Due Diligence Podcast]

My guest on the Due Diligence Podcast today is Brad O’Connor, CEO of Cogstate Ltd. (ASX: CGS) (OTCQX: COGZF). The company is an industry leader in digital cognition tests that are used primarily in drug trials to see if the drug is impacting cognition. The company operates through two segments, Healthcare and Direct to Consumer, as a provider of digital cognition tests for Alzheimer’s disease clinical trials, and direct to consumer via its global commercial partner Eisai Co., Ltd with the recently announced Digital Tool “CogMate™” in Taiwan And Hong Kong. With the recent FDA approval of Aduhelm to address the underlying biology of the disease, the first of its kind, Alzheimer’s disease and other neurodegenerative disorders had a major breakthrough. Cogstate seeks to capitalize on this secular bull market in Alzheimer’s R&D and commercialization without being a drug development company themselves. Brad O’Connor has a background you wouldn’t expect, as he does not come from the Healthcare industry, and he has a very unique perspective on growing the business. Brad and I discuss the following topics: - Alzheimer’s R&D and Commercialization - how the clinical trials are set up? - Creating digital cognition tests for the consumer - Barrier to entries for digital cognition testing market - Data and analytics opportunities With that, please enjoy my conversation with Brad O’Connor, CEO of Cogstate. For more information about Cogstate Ltd., please visit: https://www.cogstate.com/ This podcast was recorded and is being made available by SNN, Inc. (together with its affiliates and its and their employees, “SNN”) solely for informational purposes. SNN is not providing or undertaking to provide any financial, economic, legal, accounting, tax, or other advice in or by virtue of this podcast. The information, statements, comments, views, and opinions provided in this podcast are general in nature, and such information, statements, comments, views, and opinions, and the viewing of/listening to this podcast are not intended to be and should not be construed as the provision of investment advice by SNN. The information, statements, comments, views, and opinions expressed in this podcast do not constitute and should not be construed as an offer to buy or sell any securities or to make or consider any investment or other course of action. The information, statements, comments, views, and opinions expressed in this podcast (including by guest speakers who are not officers, employees, or agents of SNN) are not necessarily those of SNN and may not be current. Reference to any specific third-party entity, product, service, materials, or content does not constitute an endorsement or recommendation by the SNN. SNN assumes no responsibility or liability for the accuracy or completeness of the content contained in third party materials or on third party sites referenced in this podcast or the compliance with applicable laws of such materials and/or links referenced herein. The views expressed by guest speakers are their own and their appearance on this podcast does not imply an endorsement of them or any entity they represent. SNN does not make any representation or warranty as to the accuracy or completeness of any of the information, statements, comments, views, or opinions contained in this podcast, which may include forward-looking statements where actual results may differ materially. SNN does not undertake any obligation whatsoever to provide any form of update, amendment, change, or correction to any of the information, statements, comments, views or opinions set forth in this podcast. SNN EXPRESSLY DISCLAIMS ANY AND ALL LIABILITY OR RESPONSIBILITY FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR OTHER DAMAGES ARISING OUT OF ANY INDIVIDUAL’S USE OF, REFERENCE TO, RELIANCE ON, OR INABILITY TO USE, THIS PODCAST OR THE INFORMATION PRESENTED IN THIS PODCAST. By accessing this podcast, the listener acknowledges that the entire c